Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects

Overview

About this study

To assess if oral nizatidine or lisinopril alone and in combination will increase heme oxygenase 1 (HO-1) protein concentration and activity compared to placebo in healthy subjects.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion criteria:

  • Healthy subjects without clinical evidence of significant cardiovascular, gastrointestinal, hematological, neurological, psychiatric or other disease that may interfere with the objectives of the study and/or pose safety concerns
  • Normal serum potassium and estimated glomerular filtration rate (eGFR) > 60 ml/minute
  • Baseline systolic BP ≥ 110 mmHg
  • No known hypersensitivity to lisinopril or nizatidine
  • Able to provide written informed consent before participating in the study
  • Able to communicate adequately with the investigator and to comply with the requirements for the entire study.

Exclusion criteria:

  • Pregnant
  • Breast feeding
  • Current smoker
  • Symptoms of functional GI disorder as assessed by a validated questionnaire
  • Previous history of peptic ulcer disease.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Adil Bharucha, M.B.B.S., M.D.

Closed for enrollment

Contact information:

Kimberly Krull CCRP

(507)293-3905

Krull.Kimberly@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20142438

Mayo Clinic Footer